Good decisions require good information
Find hidden gems and smart strategies from top experts when you join Seeking Alpha.
NVS Novartis AGStock Price & Overview
$106.13
Charts
Quant Ranking
NVS Analysis
NVS News
Latest Headlines
Ratings Summary
People Also Follow
Similar to NVS
ETFs Holding NVS
NVS Company Profile
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
NVS Revenue
NVS Earnings Per Share
Earnings Estimates
Earnings Revisions
Valuation
Growth
Profitability
Momentum
Capital Structure
NVS Dividend Growth History
NVS Ownership
NVS Peers
Risk
Technicals
NVS Transcripts
Investor Presentations
NVS SEC Filings
Press Releases
NVS Income Statement
NVS Balance Sheet
NVS Cash Flow Statement
NVS Long Term Solvency
Discover More
You may be interested in: